NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Forecast, Price & News $4.59 +0.13 (+2.91%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$4.52▼$4.7150-Day Range$4.21▼$7.8752-Week Range$4.18▼$60.00Volume13,350 shsAverage Volume48,670 shsMarket Capitalization$3.95 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcadia Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside313.9% Upside$19.00 Price TargetShort InterestHealthy2.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 4 Articles This WeekInsider TradingAcquiring Shares$21,550 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($18.44) to ($6.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.53 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Arcadia Biosciences has a forecasted upside of 313.9% from its current price of $4.59.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.08% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 69.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RKDA. Previous Next 3.1 News and Social Media Coverage News SentimentArcadia Biosciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,550.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 13.33% of the stock of Arcadia Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcadia Biosciences are expected to grow in the coming year, from ($18.44) to ($6.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcadia Biosciences (NASDAQ:RKDA) StockArcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include GoodWheat pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.Read More Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RKDA Stock News HeadlinesJune 1, 2023 | americanbankingnews.comStanley Jacot, Jr. Acquires 5,000 Shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA) StockJune 1, 2023 | americanbankingnews.com10X Capital Venture Acquisition Corp. II (NASDAQ:VCXA) and Arcadia Biosciences (NASDAQ:RKDA) Head-To-Head ReviewJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 12, 2023 | marketwatch.com8-K: Arcadia Biosciences, Inc.May 12, 2023 | finance.yahoo.comQ1 2023 Arcadia Biosciences Inc Earnings CallMay 11, 2023 | seekingalpha.comArcadia Biosciences reports Q1 resultsMay 11, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces First Quarter 2023 Financial Results from Operations and Business HighlightsMay 10, 2023 | americanbankingnews.comArcadia Biosciences (RKDA) to Release Earnings on ThursdayJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 9, 2023 | americanbankingnews.comArcadia Biosciences (RKDA) Set to Announce Quarterly Earnings on ThursdayMay 8, 2023 | finance.yahoo.comGoodWheat™ Pasta Named "Best New Product" By Retail Dietitians Business AllianceApril 28, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Date of First Quarter 2023 Financial Results and Business Highlights Conference CallApril 23, 2023 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.comApril 19, 2023 | americanbankingnews.comHC Wainwright Weighs in on Arcadia Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:RKDA)April 15, 2023 | msn.comHC Wainwright & Co. Maintains Arcadia Biosciences (RKDA) Buy RecommendationApril 15, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)April 9, 2023 | finance.yahoo.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2022 Earnings Call TranscriptApril 7, 2023 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Receives New Coverage from Analysts at StockNews.comApril 3, 2023 | americanbankingnews.comLake Street Capital Trims Arcadia Biosciences (NASDAQ:RKDA) Target Price to $20.00March 31, 2023 | msn.comArcadia Biosciences's Return On Capital Employed InsightsMarch 30, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2022 Financial Results and Business HighlightsMarch 29, 2023 | benzinga.comEarnings Preview For Arcadia BiosciencesMarch 22, 2023 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.comMarch 4, 2023 | benzinga.comArcadia Biosciences Shares Resume Trade Following Circuit Breaker, Stock Now Up 56%March 3, 2023 | msn.comWhy Heritage Insurance Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving PremarketMarch 2, 2023 | marketwatch.comArcadia Biosciences Surges 77% in Second Day After Reverse SplitMarch 1, 2023 | finance.yahoo.comWe're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash WiselySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RKDA Company Calendar Last Earnings3/30/2023Today6/01/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Agricultural production - crops Sub-IndustryN/A SectorBasic Materials Current SymbolNASDAQ:RKDA CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees58Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+313.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($28.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,380,000.00 Net Margins-245.87% Pretax Margin-247.08% Return on Equity-63.53% Return on Assets-44.08% Debt Debt-to-Equity RatioN/A Current Ratio6.64 Quick Ratio6.01 Sales & Book Value Annual Sales$9.96 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value$19.46 per share Price / Book0.24Miscellaneous Outstanding Shares860,000Free Float841,000Market Cap$3.95 million OptionableNot Optionable Beta0.97 Key ExecutivesStanley E. JacotPresident, Chief Executive Officer & DirectorBelinda YaoVice President-OperationsThomas J. SchaeferChief Financial OfficerBrett MichelGeneral ManagerLaura PitlikChief Marketing OfficerKey CompetitorsIT Tech PackagingNYSE:ITPVenator MaterialsNYSE:VNTRQVenator MaterialsNYSE:VNTRTantechNASDAQ:TANHExcellon ResourcesNYSE:EXNView All CompetitorsInsiders & InstitutionsStanley Jacot JrBought 5,000 shares on 5/30/2023Total: $21,550.00 ($4.31/share)Armistice Capital LLCSold 454,994 shares on 5/16/2023Ownership: 9.615%Sabby Management LLCBought 52,874 shares on 5/16/2023Ownership: 6.162%State Street CorpSold 89,654 shares on 5/16/2023Ownership: 1.416%Simplex Trading LLCSold 1,000 shares on 4/27/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RKDA Stock - Frequently Asked Questions Should I buy or sell Arcadia Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares. View RKDA analyst ratings or view top-rated stocks. What is Arcadia Biosciences' stock price forecast for 2023? 1 equities research analysts have issued 12-month price targets for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $18.00 to $20.00. On average, they predict the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 313.9% from the stock's current price. View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts. How have RKDA shares performed in 2023? Arcadia Biosciences' stock was trading at $0.2710 at the start of the year. Since then, RKDA stock has increased by 1,593.7% and is now trading at $4.59. View the best growth stocks for 2023 here. Are investors shorting Arcadia Biosciences? Arcadia Biosciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 12,400 shares, a decline of 69.8% from the April 30th total of 41,000 shares. Based on an average daily trading volume, of 167,500 shares, the short-interest ratio is presently 0.1 days. Approximately 2.1% of the company's stock are short sold. View Arcadia Biosciences' Short Interest. When is Arcadia Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our RKDA earnings forecast. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its earnings results on Thursday, March, 30th. The basic materials company reported ($6.31) earnings per share (EPS) for the quarter. The basic materials company earned $1 million during the quarter. Arcadia Biosciences had a negative net margin of 245.87% and a negative trailing twelve-month return on equity of 63.53%. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO? 1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Arcadia Biosciences IPO? (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO. What is Arcadia Biosciences' stock symbol? Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA." Who are Arcadia Biosciences' major shareholders? Arcadia Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.62%), Sabby Management LLC (6.16%), State Street Corp (1.42%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer. View institutional ownership trends. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcadia Biosciences' stock price today? One share of RKDA stock can currently be purchased for approximately $4.59. How much money does Arcadia Biosciences make? Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.95 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($28.77) on an earnings per share basis. How can I contact Arcadia Biosciences? Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027. This page (NASDAQ:RKDA) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.